No. of patients randomized
(n=50)

arm A (n=25)

25 treated with induction of Carboplatin+Paclitaxel

- 8 discontinued during induction phase
- 5 disease progression
- 2 physician decision
- 1 persistent anemia

17 completed induction chemotherapy

- 5 not treated with maintenance therapy
- 3 disease progression
- 1 persistent anemia
- 1 complicated disease

12 treated with maintenance therapy

- 12 discontinued treatment
- 5 disease progression
- 2 physician’s decision
- 2 complicated disease of bacterial pneumonia
- 2 repeated or persistent neutropenia
- 1 patient’s refusal

arm B (n=25)

25 treated with induction of Carboplatin+Gemcitabine

- One excluded from analysis due to protocol violation

13 discontinued during induction phase
- 3 disease progression
- 4 hematologic adverse events
- 3 complicated diseases
- 2 ALT elevation
- 1 physician’s decision

12 completed induction chemotherapy

- 3 not treated with maintenance therapy
- 3 disease progression

8 treated with maintenance therapy

- 8 discontinued treatment
- 6 disease progression
- 1 physician’s decision
- 1 persistent anemia